# Metformin Treatment in Progressive Multiple Sclerosis

> **NCT05349474** · EARLY_PHASE1 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 23 (actual)

## Conditions studied

- Secondary Progressive Multiple Sclerosis
- Primary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Metformin 500 Mg Oral Tablet, up to 4 tablets a day
- **DRUG:** Placebo oral tablet identical to metformin, up to 4 tablets a day

## Key facts

- **NCT ID:** NCT05349474
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-26
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-05-30
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05349474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05349474, "Metformin Treatment in Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05349474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*